Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
Conditions
- HER2-positive Breast Cancer
- Recurrent Breast Cancer
- Recurrent Non-small Cell Lung Cancer
- Recurrent Ovarian Epithelial Cancer
- Recurrent Ovarian Germ Cell Tumor
- Stage IV Breast Cancer
- Stage IV Non-small Cell Lung Cancer
- Stage IV Ovarian Epithelial Cancer
- Stage IV Ovarian Germ Cell Tumor
Interventions
- DRUG: ex vivo-expanded HER2-specific T cells
- DRUG: cyclophosphamide
- BIOLOGICAL: denileukin diftitox
- OTHER: flow cytometry
- OTHER: immunoenzyme technique
Sponsor
University of Washington
Collaborators